ojrdrtОнкологический журнал: лучевая диагностика, лучевая терапияJournal of oncology: diagnostic radiology and radiotherapy2587-75932713-167XНЕКОММЕРЧЕСКОЕ ПАРТНЕРСТВО «ОБЩЕСТВО ИНТЕРВЕНЦИОННЫХ ОНКОРАДИОЛОГОВ»10.37174/2587-7593-2026-9-1-103-108ojrdrt-519Research ArticleКЛИНИЧЕСКИЕ СЛУЧАИCLINICAL CASESСравнение ПЭТ/КТ с ⁶⁸Ga-FAPI-04 и ⁶⁸Ga-FAP-2286 in vivо при воспалительном и онкологическом заболеваниях. Клинические наблюденияComparison of PET/CT with ⁶⁸Ga-FAPI-04 and ⁶⁸Ga-FAP-2286 in vivo for inflammatory and oncological diseases. Clinical caseshttps://orcid.org/0000-0001-7226-5129ТулинП. Е.TulinP. E.

115478 Москва, Каширское шоссе, 24

24 Kashirskoe Shosse, Moscow 115478

p.tulin@ronc.ruhttps://orcid.org/0009-0002-0651-9711ДеньгинаТ. А.DenginaT. A.

115478 Москва, Каширское шоссе, 24

24 Kashirskoe Shosse, Moscow 115478

https://orcid.org/0009-0007-6294-5826СоломяныйВ. В.SolomyanyV. V.

115478 Москва, Каширское шоссе, 24

24 Kashirskoe Shosse, Moscow 115478

https://orcid.org/0009-0001-6694-9564ФилимоновА. В.FilimonovA. V.

115478 Москва, Каширское шоссе, 24

24 Kashirskoe Shosse, Moscow 115478

https://orcid.org/0000-0003-2969-0191НевзоровД. И.NevzorovD. I.

115478 Москва, Каширское шоссе, 24

24 Kashirskoe Shosse, Moscow 115478

https://orcid.org/0000-0001-7185-7165ДолгушинБ. И.DolgushinB. I.

115478 Москва, Каширское шоссе, 24

24 Kashirskoe Shosse, Moscow 115478

Национальный медицинский исследовательский центp онкологии им. Н.Н. Блохина Минздрава РоссииРоссияN.N. Blokhin National Medical Research Center of OncologyRussian Federation20262803202691103108Copyright © Тулин П.Е., Деньгина Т.А., Соломяный В.В., Филимонов А.В., Невзоров Д.И., Долгушин Б.И., 20262026Тулин П.Е., Деньгина Т.А., Соломяный В.В., Филимонов А.В., Невзоров Д.И., Долгушин Б.И.Tulin P.E., Dengina T.A., Solomyany V.V., Filimonov A.V., Nevzorov D.I., Dolgushin B.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.oncoradjournal.ru/jour/article/view/519

Цель: Изучить фармакокинетику ⁶⁸Ga‑FAP‑2286 при опухолевом и воспалительном заболеваниях, сравнить диагностические возможности ⁶⁸Ga‑FAP‑2286 и ⁶⁸Ga‑FAPI‑04, в том числе в аспекте потенциального использования для отбора пациентов для радионуклидной терапии 177Lu‑FAP‑2286. Материалы и методы: Двум пациентам — с онкологическим заболеванием и с воспалительным процессом — проведены ПЭТ/КТ‑исследования с ⁶⁸Ga‑FAP‑2286 и ⁶⁸Ga‑FAPI‑04. ПЭТ/КТ‑сканирование с ⁶⁸Ga‑FAP‑2286 проведено в три этапа — через 5 мин, через 60 мин и 180 мин после введения РФЛП с последующей оценкой динамики изменения показателя SUVmax в таргетных областях. ПЭТ/КТ‑сканирование с ⁶⁸Ga‑FAPI‑04 проведено в один этап — через 60 мин. Заключение: ⁶⁸Ga‑FAPI‑04 и ⁶⁸Ga‑FAP‑2286 обладают схожими диагностическими характеристиками. Также были выявлены различия в фармакокинетике ⁶⁸Ga‑FAP‑2286 в опухолевых и воспалительных изменениях.

Purpose: To study the pharmacokinetics of ⁶⁸Ga‑FAP‑2286 in oncological and inflammatory diseases and to compare the diagnostic capabilities of ⁶⁸Ga‑FAP‑2286 and ⁶⁸Ga‑FAPI‑04, including in the context of its potential use for patient selection for 177Lu‑FAP‑2286 radionuclide therapy. Material and methods: PET/CT studies with ⁶⁸Ga‑FAP‑2286 and ⁶⁸Ga‑FAPI‑04 were performed on two patients: one with an oncological disease and one with an inflammatory process. The ⁶⁸Ga‑FAP‑2286 PET/CT scan was conducted in three phases — at 5 minutes, 60 minutes, and 180 minutes after radiopharmaceutical administration, followed by an assessment of the dynamics of SUVmax changes in the target regions. PET/CT scanning with ⁶⁸Ga‑FAPI‑04 was performed in a single step, 60 minutes post‑injection Conclusion: ⁶⁸Ga‑FAPI‑04 and ⁶⁸Ga‑FAP‑2286 have similar diagnostic characteristics. Differences in the pharmacokinetics of ⁶⁸Ga‑FAP‑2286 between tumorous and inflammatory changes were also identified.

ПЭТ/КТпозитронная эмиссионная томография⁶⁸Ga‑FAPI‑04⁶⁸Ga‑FAP‑2286PET/CTpositron emission tomography⁶⁸Ga‑FAPI‑04⁶⁸Ga‑FAP‑2286ReferencesБелкин ЕВ, Тулин ПЕ, Абу‑Хайдар ОБ. ПЭТ/КТ с ⁶⁸Ga‑FAPI и 18F‑FDG в оценке метастатического поражения регионарных лимфоузлов при раке желудка. Онкологический журнал: лучевая диагностика, лучевая терапия. 2025;8(1):29‑35.Belkin EV, Tulin PE, Abu‑Khaydar OB. PET/CT with ⁶⁸Ga‑FAPI and 18F‑FDG in the Detection of Metastases in Regional Lymph Nodes in Gastric Cancer. Journal of Oncology: Diagnostic Radiology and Radiotherapy. 2025;8(1):29‑35. (In Russ.). https://doi.org/10.37174/2587‑7593‑2025‑8‑1‑29‑35Тулин ПЕ, Поляков АН, Пронин АИ. ПЭТ/КТ с ⁶⁸Ga‑FAPI в диагностике рака неизвестной первичной локализации. Клиническое наблюдение. Онкологический журнал: лучевая диагностика, лучевая терапия. 2023;6(4):99‑104.Tulin PE, Polyakov AN, Pronin AI. PET/CT with ⁶⁸Ga‑FAPI in the Diagnosis of Cancer of Unknown Primary Localization. Clinical Case. Journal of Oncology: Diagnostic Radiology and Radiotherapy. 2023;6(4):99‑104. (In Russ.). https://doi.org/10.37174/2587‑7593‑2023‑6‑4‑99‑104Wang H, Zhu W, Ren S, et al. ⁶⁸Ga‑FAPI‑04 versus 18F‑FDG PET/CT in the detection of hepatocellular carcinoma. Frontiers in Oncology, 11, 2021;693640. https://doi.org/10.3389/fonc.2021.693640Wang H, Zhu W, Ren S, et al. ⁶⁸Ga‑FAPI‑04 versus 18F‑FDG PET/CT in the detection of hepatocellular carcinoma. Frontiers in Oncology, 11, 2021;693640. https://doi.org/10.3389/fonc.2021.693640Elboga U, Sahin E, Kus T, et al. Superiority of ⁶⁸Ga‑FAPI PET/CT scan in detecting additional lesions compared to 18FDG PET/CT scan in breast cancer. Annals of Nuclear Medicine 35, 2021;1321‑31. https://doi.org/10.1007/s12149‑021‑01672‑xElboga U, Sahin E, Kus T, et al. Superiority of ⁶⁸Ga‑FAPI PET/CT scan in detecting additional lesions compared to 18FDG PET/CT scan in breast cancer. Annals of Nuclear Medicine 35, 2021;1321‑31. https://doi.org/10.1007/s12149‑021‑01672‑xKessler L, Hirmas N, Pabst KM, et al. ⁶⁸Ga‑Labeled fibroblast activation protein inhibitor (⁶⁸Ga‑FAPI) PET for pancreatic adenocarcinoma: data from the ⁶⁸Ga‑FAPI PET observational trial. Journal of Nuclear Medicine, 2023;64(12):1910‑17. https://doi.org/10.2967/jnumed.122.264827Kessler L, Hirmas N, Pabst KM, et al. ⁶⁸Ga‑Labeled fibroblast activation protein inhibitor (⁶⁸Ga‑FAPI) PET for pancreatic adenocarcinoma: data from the ⁶⁸Ga‑FAPI PET observational trial. Journal of Nuclear Medicine, 2023;64(12):1910‑17. https://doi.org/10.2967/jnumed.122.264827Loktev A, Lindner T, Burger EM, et al. Development of fibroblast activation protein–targeted radiotracers with improved tumor retention. Journal of Nuclear Medicine, 2019;60(10):1421‑9. https://doi.org/10.2967/jnumed.118.224469Loktev A, Lindner T, Burger EM, et al. Development of fibroblast activation protein–targeted radiotracers with improved tumor retention. Journal of Nuclear Medicine, 2019;60(10):1421‑9. https://doi.org/10.2967/jnumed.118.224469Fu K, Pang Y, Zhao L, et al. FAP‑targeted radionuclide therapy with [177Lu]Lu‑FAPI‑46 in metastatic nasopharyngeal carcinoma. European Journal of Nuclear Medicine & Molecular Imaging 49, 2022;1767‑9 https://doi.org/10.1007/s00259‑021‑05634‑3Fu K, Pang Y, Zhao L, et al. FAP‑targeted radionuclide therapy with [177Lu]Lu‑FAPI‑46 in metastatic nasopharyngeal carcinoma. European Journal of Nuclear Medicine & Molecular Imaging 49, 2022;1767‑9 https://doi.org/10.1007/s00259‑021‑05634‑3Zboralski D, Hoehne A, Bredenbeck A, et al. Preclinical evaluation of FAP‑2286 for fibroblast activation protein targeted radionuclide imaging and therapy. European Journal of Nuclear Medicine & Molecular Imaging 49, 2022;3651‑67. https://doi.org/10.1007/s00259‑022‑05842‑5Zboralski D, Hoehne A, Bredenbeck A, et al. Preclinical evaluation of FAP‑2286 for fibroblast activation protein targeted radionuclide imaging and therapy. European Journal of Nuclear Medicine & Molecular Imaging 49, 2022;3651‑67. https://doi.org/10.1007/s00259‑022‑05842‑5Yizhen P, Liang Zh, Tinghua M, et al. Journal of Nuclear Medicine, 2023;64 (3):386‑94. https://doi.org/10.2967/jnumed.122.264544Yizhen P, Liang Zh, Tinghua M, et al. Journal of Nuclear Medicine, 2023;64 (3):386‑94. https://doi.org/10.2967/jnumed.122.264544Kline B, Yadav S, Seo Y, et al. ⁶⁸Ga‑FAP‑2286 PET of Solid Tumors: Bio‑ distribution, Dosimetry, and Comparison with 18F‑FDG. Journal of Nuclear Medicine, 2024;65(6):938‑943. https://doi.org/10.2967/jnumed.123.267281; PMID: 38697672; PMCID: PMC11149593Kline B, Yadav S, Seo Y, et al. ⁶⁸Ga‑FAP‑2286 PET of Solid Tumors: Bio‑ distribution, Dosimetry, and Comparison with 18F‑FDG. Journal of Nuclear Medicine, 2024;65(6):938‑943. https://doi.org/10.2967/jnumed.123.267281; PMID: 38697672; PMCID: PMC11149593Pang Y, Zhao L, Meng T, et al. PET imaging of fibroblast activation protein in various types of cancer using ⁶⁸Ga‑FAP‑2286: comparison with 18F‑FDG and ⁶⁸Ga‑FAPI‑46 in a single‑center, prospective study. Journal of Nuclear Medicine, 2023;64(3):386‑94. https://doi.org/10.2967/jnumed.122.264544Pang Y, Zhao L, Meng T, et al. PET imaging of fibroblast activation protein in various types of cancer using ⁶⁸Ga‑FAP‑2286: comparison with 18F‑FDG and ⁶⁸Ga‑FAPI‑46 in a single‑center, prospective study. Journal of Nuclear Medicine, 2023;64(3):386‑94. https://doi.org/10.2967/jnumed.122.264544

The authors declare that there are no conflicts of interest present.